• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Access in all areas? A roundup of developments in market access and health technology assessment: part 6.全面准入？市场准入与卫生技术评估进展综述：第6部分。
J Comp Eff Res. 2025 Mar;14(3):e240239. doi: 10.57264/cer-2024-0239. Epub 2025 Jan 10.
2
Health Technology Assessment (HTA) and Access Policies.健康技术评估（HTA）和准入政策。
Eur J Health Law. 2020 May 7;27(3):274-289. doi: 10.1163/15718093-BJA10006.
3
Access in all areas? A round up of developments in market access and health technology assessment: part 1.全覆盖准入政策？市场准入和卫生技术评估发展综述：第 1 部分。
J Comp Eff Res. 2023 Oct;12(10):e230129. doi: 10.57264/cer-2023-0129. Epub 2023 Aug 16.
4
The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment.在欧洲联合临床卫生技术评估中，附加人群、干预、对照和结局的影响。
Value Health. 2024 Dec;27(12):1722-1731. doi: 10.1016/j.jval.2024.07.024. Epub 2024 Aug 10.
5
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges.绘制欧盟联合临床评估与地方卫生技术评估决策之间的方法差距：对部分欧盟市场指南及协调挑战的环境扫描
J Comp Eff Res. 2025 May;14(5):e240240. doi: 10.57264/cer-2024-0240. Epub 2025 Feb 26.
6
Health technology assessment of medical devices: What is different? An overview of three European projects.医疗设备的卫生技术评估：有何不同？三个欧洲项目概述。
Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):309-18. doi: 10.1016/j.zefq.2015.06.011. Epub 2015 Jul 26.
7
Advancing cooperation in Health Technology Assessment in Europe: insights from the EUnetHTA 21 project amidst the evolving legal landscape of European HTA.推进欧洲卫生技术评估合作：在欧洲卫生技术评估不断演变的法律环境中，来自欧盟卫生技术评估网络21项目的见解。
Int J Technol Assess Health Care. 2024 Dec 12;40(1):e75. doi: 10.1017/S0266462324004689.
8
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.基于组织学的癌症药物建模方法，为 NICE 评估提供信息：系统评价和决策框架。
Health Technol Assess. 2021 Dec;25(76):1-228. doi: 10.3310/hta25760.
9
Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient Access.理解英国国家卫生与临床优化研究所严重程度附加费：探索其实施及其对决策和患者获得的影响。
Value Health. 2024 Jun;27(6):730-736. doi: 10.1016/j.jval.2024.02.013. Epub 2024 Mar 4.
10
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy.探索成功实施欧盟 HTA 法规的路径：2023 年欧洲准入学院春季大会的主要收获。
Health Res Policy Syst. 2024 Jul 2;22(1):74. doi: 10.1186/s12961-024-01154-2.

引用本文的文献

1
Access in all areas? A round up of developments in market access and health technology assessment: part 7.全面准入？市场准入与卫生技术评估发展综述：第7部分。
J Comp Eff Res. 2025 Jun;14(6):e250043. doi: 10.57264/cer-2025-0043. Epub 2025 Apr 14.

本文引用的文献

1
Does NICE's "severity modifier" for assessing diseases need to change?英国国家卫生与临床优化研究所（NICE）用于评估疾病的“严重程度修正因子”是否需要更改？
BMJ. 2024 Nov 22;387:q2620. doi: 10.1136/bmj.q2620.
2
Access in all areas? A round up of developments in market access and HTA: part 5.全覆盖准入政策？市场准入和 HTA 发展综述：第 5 部分。
J Comp Eff Res. 2024 Nov;13(11):e240179. doi: 10.57264/cer-2024-0179. Epub 2024 Oct 1.
3
The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment.在欧洲联合临床卫生技术评估中，附加人群、干预、对照和结局的影响。
Value Health. 2024 Dec;27(12):1722-1731. doi: 10.1016/j.jval.2024.07.024. Epub 2024 Aug 10.
4
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?欧盟卫生技术评估联合临床评估：罕见病患者会因此处于劣势吗？
J Comp Eff Res. 2024 Jun;13(6):e240052. doi: 10.57264/cer-2024-0052. Epub 2024 May 2.
5
Is the price right? Paying for value today to get more value tomorrow.价格合理吗？今天为价值买单，明天收获更多价值。
BMC Med. 2024 Jan 30;22(1):45. doi: 10.1186/s12916-024-03262-w.
6
The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain.英国、法国、德国、意大利和西班牙的卫生技术评估机构对肿瘤学中间接治疗比较方法的接受情况。
Pharmacoecon Open. 2024 Jan;8(1):5-18. doi: 10.1007/s41669-023-00455-6. Epub 2023 Dec 14.
7
Access in all areas? A round up of developments in market access and health technology assessment: part 1.全覆盖准入政策？市场准入和卫生技术评估发展综述：第 1 部分。
J Comp Eff Res. 2023 Oct;12(10):e230129. doi: 10.57264/cer-2023-0129. Epub 2023 Aug 16.
8
The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.卫生技术评估的发展变化：对 NICE 新方法手册的批判性评价。
Value Health. 2023 Oct;26(10):1503-1509. doi: 10.1016/j.jval.2023.05.015. Epub 2023 Jun 1.
9
A review of HTA guidelines on societal and novel value elements.关于 HTA 指南中社会和新颖价值要素的综述。
Int J Technol Assess Health Care. 2023 May 25;39(1):e31. doi: 10.1017/S026646232300017X.
10
Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].医疗保健价值的定义要素——一种卫生经济学方法：一份ISPOR特别工作组报告[3]
Value Health. 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007.

全面准入？市场准入与卫生技术评估进展综述：第6部分。

Access in all areas? A roundup of developments in market access and health technology assessment: part 6.

作者信息

Pannelay Annie Jullien, Gilardino Ramiro E, Ramagopalan Sreeram V

机构信息

ProductLife Group, Immeuble Colisée Gardens, 10 Av. de l'Arche Bâtiment C, 7ème étage, 92400 Courbevoie, France.

School of Public Health, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, C1121 ABG, Cdad. Autónoma de Buenos Aires, Argentina.

出版信息

J Comp Eff Res. 2025 Mar;14(3):e240239. doi: 10.57264/cer-2024-0239. Epub 2025 Jan 10.

DOI:10.57264/cer-2024-0239
PMID:39791858
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11864082/
Abstract

In this update, we discuss an article covering the implementation challenges of the upcoming European Union Health Technology Assessment regulation, particularly focusing on the complexity of population, intervention, comparator and outcomes requirements across member states; a user guide to applying generalized cost-effectiveness analysis for broader value assessment and finally highlight an ongoing debate surrounding National Institute for Health and Care Excellence's severity modifier implementation.

摘要

在本次更新中，我们讨论一篇文章，该文章涵盖即将出台的欧盟卫生技术评估法规的实施挑战，尤其关注各成员国在人群、干预措施、对照物和结果要求方面的复杂性；一份关于应用广义成本效益分析进行更广泛价值评估的用户指南，最后突出围绕英国国家卫生与临床优化研究所严重程度修正因子实施的持续辩论。